Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell 2Oligodendroglioma 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Inflammatory Breast Neoplasms 1Immunoblastic Lymphadenopathy 1Gliosarcoma 1Glioblastoma 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 5Brentuximab Vedotin 5Vincristine 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Ifosfamide 4Etoposide 4Doxorubicin 4Carboplatin 4romidepsin 3fludarabine phosphate 3brigatinib 3Prednisone 3Lenalidomide 3Everolimus 310-propargyl-10-deazaaminopterin 3pembrolizumab 2indolepropanol phosphate 2Whole-Body Irradiation 2Vorinostat 2Mycophenolic Acid 2Microarray Analysis 2Immunohistochemistry 2Gene Expression Profiling 2Cytarabine 2Cyclosporine 2Clofarabine 2Bendamustine Hydrochloride 2veliparib 1repotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Large-Cell, Anaplastic × Depsipeptides × Clear all
NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
39 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡